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Introduction
Th e pathology of Alzheimer’s disease (AD) accumulates 
decades before the clinical symptoms start to appear. 
Extra cellular amyloid deposits and intracellular neuro-
fi brillary tangles are the classic hallmarks of AD. Th ere 
are well established genetic markers for early onset AD 
but more than 95% of AD patients suff er from the 
sporadic form. Th e aetiology of the sporadic form of AD 
has been understood to be multifactorial and is infl u-
enced by various genetic, biochemical and environmental 
factors. Prediction of future pathological cognitive 
decline in AD is of critical importance as it would allow 
for current and future prevention and treatment 
strategies to be initiated when they are likely most 
eff ective - and would also have applications in monitoring 
of medical and lifestyle interventions. It has been 
demonstrated earlier that AD biomarkers can detect the 
disease long before the clinically obvious symptoms 
appear [1]. A biomarker is objectively measured and 
evaluated as an indicator of a pathological process or 
pharmacological response to a therapeutic intervention. 
Th e sensitivity, specifi city and ease-of-use are the most 
important factors that ultimately defi ne the diagnostic 
utility of a biomarker. Th ey are important avenues to 
disease diagnosis and identifying individuals at risk. 
Identifi cation of such reliably validated biomarkers has 
led to the introduction of a diagnostic preclinical phase 
where the biomarkers are present in asymptomatic 
individuals [2].
Whilst there have been major advances in neuro-
imaging, particularly amyloid beta (Aβ) imaging, its use 
as a routine diagnostic test is cost prohibitive. As such, 
attention has switched to the periphery and readily 
accessible biological material for AD biomarker research. 
Over recent years, cerebrospinal fl uid (CSF) has been the 
major focus of proteomic biomarker discovery studies; 
however, CSF collection is a highly invasive procedure 
that is diffi  cult to implement in the clinical routine and in 
clinical trials. Th erefore, a strong interest exists for less 
invasive diagnostic approaches for AD, such as blood-
derived biomarkers. An ideal AD blood biomarker (or 
panel) should represent the associated pathological and 
biochemical changes occurring in the brain. AD blood 
biomarker research is still at an early stage of develop-
ment and clinical evaluation before it can be integrated 
into clinical practice as a key diagnostic tool. Th e 
measurement and reliability of these blood biomarkers is 
limited by the physiology of the blood brain barrier. 
Moreover, the biomarkers closely associated with disease 
pathology are found in very low concentrations in blood, 
which is furthermore compromised by the complex 
biochemical nature of the fl uid [3]. A major limitation of 
blood biomarker studies is the lack of reproducibility of 
the results. Th is review discusses the current knowledge 
on blood biomarkers in AD, focussing on the multiplex 
approach with discussion on novel strategies for 
biomarker discovery.
Abstract
Advances in the fi eld of blood biomarker discovery will 
help in identifying Alzheimer’s disease in its preclinical 
stage, allowing treatment to be initiated before 
irreversible damage occurs. This review discusses 
some recent past and current approaches being 
taken by researchers in the fi eld. Individual blood 
biomarkers have been unsuccessful in defi ning the 
disease pathology, progression and thus diagnosis. This 
directs to the need for discovering a multiplex panel of 
blood biomarkers as a promising approach with high 
sensitivity and specifi city for early diagnosis. However, 
it is a great challenge to standardize a worldwide 
blood biomarker panel due to the innate diff erences 
in the population tested, nature of the samples and 
methods utilised in diff erent studies across the globe. 
We highlight several issues that result in the lack 
of reproducibility in this fi eld of research currently 
faced by researchers. Several important measures are 
summarized towards the end of the review that can 
be taken to minimize the variability among various 
centres.
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Individual blood biomarkers
Th e quest for fi nding biomarkers for AD started with 
traditional approaches involving a single biomarker, such 
as Aβ [4-6], but the drawbacks included large inter- and 
intra-person variability and results were not consistent 
with the sporadic form of AD [7,8]. Th e results have been 
confl icting as Aβ present in plasma is also derived from 
peripheral tissues, non-neural systems and blood compo-
nents, thus constantly allowing dynamic interchange of 
Aβ between brain and periphery. Th is might be one of 
the reasons for failure of anti-amyloid interventions in 
AD, so there is a need to determine the signifi cance of 
various sources of Aβ in plasma. In addition, Aβ binds 
avidly to various plasma proteins and membranes. 
Several longitudinal and cross-sectional studies on 
plasma Aβ40 and Aβ42 show wide variations within and 
among individuals as well [9,10]. Several other factors 
also contribute to the levels of Aβ in plasma, such as diet, 
medication, stress and circadian rhythm [11].
Lately, many candidate biomarkers have been studied 
individually, such as apolipoprotein E (ApoE), apoJ, α-1 
antitrypsin, complement factors, cytokines, apoA-1 and 
many more [12]. Padovani and colleagues [13] reported 
altered levels of amyloid precursor protein in AD 
patients, showing a reduced ratio of higher to lower 
molecular weight isoforms. Th e ratio was associated with 
disease severity and progression with 80 to 90% sensi-
tivity and specifi city. Our lab reported levels of plasma 
apoE in AD in the baseline Australian Imaging Bio-
markers Lifestyle (AIBL) cohort, which indicated a strong 
relationship between apoE levels, AD and apoE4 status, 
which is known to be the greatest risk factor for AD [14]. 
Interestingly, lower levels of apoE in AD were also 
observed irrespective of apoE4 genotype, that is, in non-
apoE4 allele carriers. Another study [15] comparing 
plasma and CSF levels of apoE in AD and control subjects 
showed dependence of plasma apoE levels on apoE 
genotype. Further, plasma apoE levels did not correlate 
with CSF apoE levels, but CSF apoE did correlate with 
CSF Aβ42 levels. Th is raises the question of validation 
and interpretation of peripheral biomarkers, whose 
production and clearance may be relatively independent 
in the periphery and in the brain.
In addition to protein biomarkers, evidence on the role 
of cholesterol and cholesterol metabolism in AD 
pathology indicates that hypercholesterolemia is closely 
associated with mild cognitive impairment (MCI) and 
AD [16,17]. Studies suggest that lipid lowering agents and 
statins reduce the risk of AD [18,19]. 24S-Hydroxy-
cholesterol, a cholesterol metabolite, refl ects brain 
homeo stasis, that is, the balance between the intra- and 
extra-cerebral pools of cholesterol [20]. Certain studies 
have shown signifi cant reduction in levels of 24S-
hydroxy cholesterol in plasma [21] while others revealed 
inconsistent increases of the same compound in plasma 
[22,23] with weak correlation to CSF levels [24].
AD has a complex pathology involving several molecu-
lar pathways, such as amyloid deposition, taupathy, 
oxidative damage, infl ammation and metabolic changes. 
Th e markers of underlying pathology in all these path-
ways can serve as markers for AD. A broad range of 
markers have been studied extensively in correlation with 
AD disease pathology, conversion and progression. 
Grow ing evidence suggests that oxidation plays a crucial 
role in AD pathogenesis. Markers of oxidative damage 
are found in AD brain, including protein, lipid and 
nucleic acid oxidation products [25,26]. Isoprostanes, 
products of lipid peroxidation, have been associated with 
AD in many studies [27,28]. Results have been promising 
with CSF; F2-isoprostanes seem to increase during 
conversion from MCI to AD [29], closely associated with 
imaging and memory parameters with good sensitivity 
and specifi city [30]. Results have been inconsistent with 
regard to levels in plasma as a few studies have reported 
increased levels [31,32] while others have reported no 
signifi cant diff erence [33,34]. One possibility for the 
discrepancies may be the presence of vascular risk factors 
that can alter the levels of F2-isoprostanes [35]. It is now 
well proven that infl ammation also plays a vital role in 
AD pathology. Astroctyosis, microgliosis, complement 
activation and upregulation of acute phase proteins are 
infl ammatory responses elicited by amyloid deposition in 
brain. Measurement of these markers in blood is unclear 
as these proteins may not cross the blood brain barrier. 
Th ese makers include C-reactive protein, IL-1β, tumour 
necrosis factor-α, IL-6, IL-6 receptor complex, α1-
antichymotrypsin and transforming growth factor-β, and 
cytokines such as IL-12, interferon-α, and interferon-β 
[36]. Despite a plethora of blood biomarker literature in 
AD, these are unlikely to be diagnostically suffi  cient 
individually as they lack the required sensitivity and 
specifi city to be potential AD biomarkers.
Multiplex approach
Th ere is a defi nite need for a holistic approach for 
standardizing blood biomarkers for AD. It is crucial to 
understand the relationship between various individual 
biomarkers and move away from the traditional approach 
of investigating levels of single candidate biomarkers at a 
time. Many studies have formulated panels of biomarkers 
to distinguish between healthy and AD participants and 
evaluated broad ranges of proteins in diff erent combi na-
tions to yield high sensitivity and specifi city [37,38]. 
Th ere has been considerable development in the dis-
covery of cost-eff ective plasma protein biomarkers for 
AD [39]. In a panel of 120 signalling proteins, 18 proteins 
had 82% specifi city in diff erentiating AD from healthy 
subjects and predicting the conversion from MCI to AD 
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[40]. Tuenissen and colleagues [36] evaluated 29 serum 
biomarkers that can diff erentiate AD from healthy parti ci-
pants. Th ese included infl ammatory biomarkers such as 
IL-6 and metabolic biomarkers such as cholesterol meta-
bolites, cysteine and homocysteine. Doecke and colleagues 
[41] reported on AIBL baseline plasma screening of 151 
analytes combined with targeted biomarker and clinical 
pathology data in a total of 961 participants. An initial 
plasma biomarker panel consisting of 18 biomarkers was 
identifi ed that distinguishes individuals with AD from 
cognitively healthy controls with high sensitivity and 
specifi city. A fi nal signature panel of eight proteins (beta 
2 microglobulin, carcinoembryonic antigen, cortisol, 
epider mal growth factor receptor, IGFBP-2, IL-17, PPY 
and VCAM-1) was identifi ed that showed increased 
prediction accuracy when validated in an Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) dataset. A 
similar study [42] reported on the measured levels of 190 
plasma proteins in a total of 600 participants. An initial 
panel of 17 analytes associated with the diagnosis of very 
mild dementia/MCI or AD was identifi ed. Th eir analysis 
yielded a set of four plasma analytes (ApoE, B-type 
natriuretic peptide, C-reactive protein, pancreatic poly-
peptide) that were consistently associated with the 
diagnosis of very mild dementia/MCI/AD when validated 
across the ADNI cohort. A comparison among panels of 
analytes derived from such similar studies reveals very 
few common blood biomarkers for AD. Despite having 
similar analytical platforms and common validation 
cohorts, there are discrepancies in the numbers of plasma 
biomarkers identifi ed by these studies. Th e likely reasons 
for this could be variation in pre-analytical variable selec-
tion, which could lead to diff erential interaction between 
analytes of interest, diff erences in innate characteristics 
of a cohort based on region and diff erent statistical 
approaches employed by the diff erent groups.
Th ere are diff erent methods for identifying biomarkers 
in blood (Table 1); hence, it is important to standardize 
the methods of generation of proteomic data and the 
entire workfl ow. In order to standardize a panel of bio-
markers for AD diagnosis, consensus on protocols and 
ultra sensitive analytical methods are required through 
multi centre studies. Proteins in a sample can be separated 
using two-dimensional polyacrylamide gel electro-
phoresis or high performance liquid chromato graphy 
[43]; surface chromatography by adsorbing proteins to 
activated surfaces (surface-enhanced or matrix-assisted 
laser desorption-ionization protein chip array tech-
nology) [44]; and peptide ionization procedures for 
analysis of proteins from gels or protein chips by mass 
spectroscopy (MS). Each technology has its own 
advantages and limitations. For example, researchers use 
two-dimen sional gel electrophoresis-MS for plasma 
biomarker analysis because of its remarkable resolving 
power, increased sensitivity and high throughput 
proteome analy sis capabilities [37,45], and although this 
technology is usually accessible to most of the 
researchers, it is laborious and not applicable for small 
and hydrophobic peptides. In addition there is a limited 
dynamic range for quantitative measurement. Recent 
studies have been exploring liquid chromatography-MS 
because it requires only small amounts of sample and is 
highly sensitive. Complex quantifi cation analysis and 
sensitivity for interfering compounds are the drawbacks 
for this technique. Surface enhanced laser desorption/
ionization-time of fl ight MS is a newly introduced 
protein identi fi cation technique with better resolution 
and quantifi  ca tion and selective capture of proteins 
under native conditions, although the post-processing is 
a complex procedure and reproducibility is still proble-
matic. Enzyme-linked immunosorbent assay (ELISA) is 
one of the major proteomic techniques used worldwide 
for quantifi cation of proteins but the major disadvantage 
is the availability of specifi c antibodies.
Challenges associated with standardization and 
validation of the results
Although an overwhelming volume of research has been 
done in the fi eld of AD blood biomarkers so far, there is a 
clear lack of reproducibility of the results obtained across 
diff erent studies. Firstly, diff ering methods of collection, 
transport and storage of samples may be one of the 
reasons for the observed diff erences. AIBL study protocol 
involves overnight fasting for the participants; the same 
is not the case, however, for other well characterized 
cohorts such as the Texas Alzheimer’s Research and Care 
Consortium (TARCC). Long-term storage of the samples 
in liquid nitrogen versus -80°C freezer has an impact on 
the levels of certain protein biomarkers. Secondly, 
variations among the assay and interpretation methods 
could be another factor. Changes in the biomarker panel 
have been observed when alternative methods are used 
(for example, MS versus ELISA). Th irdly, selection 
criteria of the cohort could be another important factor. 
Th e participants recruited in diff erent studies might be at 
diff erent stages of disease pathology though the clinical 
symptoms are still concealed. Standardized neuropsycho-
logical assessments across populations to obtain unifor-
mity in recruited cohorts is lacking.
Recommendations and conclusion
AD is a multifaceted disease and biomarkers need to be 
visualized in a broader range that can correlate to the 
underlying neurodegenerative phenomenon. As AD is 
multifactorial, no single biomarker will be able to explain 
the progression or pathology of AD and hence single 
biomarker approaches have been unsuccessful in 
predicting the disease pattern. Proteomics has gained the 
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interest of researchers as a promising way to decode the 
biomarker mystery. However, the close interaction of 
various fi elds, such as lipidomics, genomics and proteo-
mics, is required to achieve an optimal AD biomarker 
panel. Th is kind of ‘multi-omic’ interdisciplinary approach 
will strikingly advance further biomarker discovery.
Further, diff erent blood fractions may be appropriate to 
study particular sets of biomarkers because of the 
diff erences in the distribution of blood-based proteins. 
Th e source of the biomarker (plasma versus serum) can 
have a large impact on the observed concentration of 
some proteins, including the ones of great interest in AD 
pathophysiology [46]. Platelets are becoming increasingly 
popular in blood biomarker research because of their 
homogenous and compartmentalized nature. Both plasma 
and serum are very heterogenous in nature and have 
complex and abundant pools of proteins such as albumin 
and IgG that can potentially interfere in achieving the 
required sensitivity for the assay.
Researchers tend to use the general term ‘AD blood 
biomarker’ for an early AD diagnosis; however, there 
exists a huge need to have a separate set of signatures to 
identify diff erent stages of AD, such as pre-clinical, 
prodromal and clinical. A unique set of blood analytes is 
required to successfully predict the conversion of pre-
clinical AD participants and also to diff erentiate controls 
from MCI progressors and those who do not progress to 
further cognitive decline. Th ese sets of biomarkers should 
then be validated against other established clinical 
correlates such as the t-tau/Aβ42 ratio from CSF and 
neuroimaging so that they can be integrated into clinical 
practice. Th is will help in the speedy and accurate 
diagnosis of sporadic AD, should be able to detect disease 
progression, and have an impact on therapeutic 
intervention, the classifi cation of diff erent stages of AD 
and the diff erentiation of AD from other dementias.
Th e following are more selected recommendations for 
multiplex biomarker researchers. First, there is a need for 
extensive longitudinal studies with the aim of studying 
biomarkers along the course of the disease spectrum. Th e 
longitudinal change in biomarkers should be examined as 
a putative biomarker itself, as has been done with 
cognitive markers. Second, well defi ned and character-
ized AD cohorts need to be established and used for 
biomarker discovery. Non-AD dementia cohorts should 
be studied in parallel to determine the overlapping and 
non-overlapping biomarker profi les between dementia 
(in general) and AD. Th ird, variations in biomarker 
measurements among diff erent labs need to be overcome 
by establishing a consensus among experts involved in 
biomarker research - the ‘Delphi method’. Th is will facili-
tate identifi cation of the challenges associated with 
standardization of the protocols and disparities in tech-
niques. Fourth, multicentre studies such as ADNI and E-
ADNI are needed. Th ese studies should adopt 
standardized neuropsychological assessments, identical 
protocols, and uniform methods of analysis and inter-
pretation of data. Fifth, combinations of blood bio-
markers, risk factors, imaging, neuropsychological 
measures and clinical data should be critically evaluated.
Th e major benefi t from a successful multiplex blood 
biomarker approach in AD would be to provide an 
inexpensive and minimally invasive diagnostic test 
capable of monitoring changes over time and responses 
to clinical interventions.
Table 1. Summary of some recent multiplex Alzheimer’s disease biomarker studies 
Author Technique Biomarkers
Doecke et al. [41] Multiplex panel: Human Discover MAP, version 1.0; RBM  151 multiplexed analytes
Watt et al. [47] Copper immobilized metal affi  nity capture and SELDI  Three candidate biomarkers in blood
Ray et al. [40] Filter based, arrayed sandwich-ELISA  Chemokines, growth factors, and infl ammation markers
Zhang et al. [48] Multidimensional LC in combination with one- and  Serum-based biomarkers
 two-dimensional PAGE
 MALDI and ESI-MS Infl ammatory response mediators
 ELISA multiplex platforms Amyloid beta
Henkel et al. [49] Anion exchange and reverse phase chromatography 12 high-abundance proteins from plasma
Choi et al. [50] Two-dimensional PAGE, western blot, and MALDI-MS Fibrinogen gamma chain and alpha1 antitrypsin
Lopez et al. [51] Affi  nity chromatography, spin columns and MALDI-MS Pattern of unidentifi ed proteins in serum
ESI-MS, electrospray ionization-mass spectrometry; LC, liquid chromatography; MALDI, matrix-assisted laser desorption/ionization; MAP, multi-analyte profi ling; RBM, 
rules based medicine; SELDI, surface enhanced laser desorption/ionization.
This article is part of a series on Peripheral Biomarkers, edited by 
Douglas Galasko. Other articles in this series can be found at 
http://alzres.com/series/biomarkers
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